Stock CMXC CELL MEDX CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Cell MedX Corp.

Equities

CMXC

US15115X1072

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 11:45:34 2024-05-03 am EDT 		5-day change 1st Jan Change
0.03 USD +36.36% Intraday chart for Cell MedX Corp. -6.25% +36.36%
Apr. 15 Cell MedX Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024 CI
Mar. 12 Cell MedX Corp. announced that it has received $0.075 million in funding CI

Valuation

Fiscal Period: May 2018 2019 2020 2021 2022 2023
Capitalization 1 7.085 4.882 34.11 17.37 6.292 0.006292
Enterprise Value (EV) 1 7.183 5.264 34.48 17.65 6.885 0.909
P/E ratio -4.38 x -5.39 x -29.9 x -18.1 x -9.01 x -0.01 x
Yield - - - - - -
Capitalization / Revenue - - 355,950,305 x 2,568,477,226 x 1,037,478,318 x 2,278,059 x
EV / Revenue - - 359,807,146 x 2,610,082,224 x 1,135,153,669 x 329,116,944 x
EV / EBITDA -5.2 x -7.86 x -33.3 x -24.4 x -10.3 x -2.04 x
EV / FCF -25.3 x -373 x -38.2 x -53.6 x -21.9 x -3.74 x
FCF Yield -3.95% -0.27% -2.62% -1.86% -4.56% -26.8%
Price to Book -6.6 x -2.75 x -22.4 x -11 x -3.13 x -0 x
Nbr of stocks (in thousands) 44,283 44,283 55,916 62,073 62,923 62,923
Reference price 2 0.1600 0.1102 0.6100 0.2798 0.1000 0.000100
Announcement Date 9/13/18 9/6/19 9/15/20 8/30/21 4/7/23 9/1/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: May 2018 2019 2020 2021 2022 2023
Net sales - - 0.0958 0.006762 0.006065 0.002762
EBITDA 1 -1.382 -0.6696 -1.037 -0.7227 -0.6705 -0.4465
EBIT 1 -1.536 -0.6702 -1.038 -0.7252 -0.6717 -0.4477
Operating Margin - - -1,083.6% -10,723.97% -11,074.91% -16,207.75%
Earnings before Tax (EBT) 1 -1.547 -0.906 -1.093 -0.9108 -0.6974 -0.495
Net income 1 -1.547 -0.906 -1.093 -0.9108 -0.6974 -0.495
Net margin - - -1,140.32% -13,469.92% -11,498.42% -17,923.32%
EPS 2 -0.0366 -0.0205 -0.0204 -0.0155 -0.0111 -0.007867
Free Cash Flow 1 -0.2835 -0.0141 -0.9025 -0.3291 -0.314 -0.2433
FCF margin - - -941.79% -4,866.25% -5,177.36% -8,808.11%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 9/13/18 9/6/19 9/15/20 8/30/21 4/7/23 9/1/23
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: May 2018 2019 2020 2021 2022 2023
Net Debt 1 0.1 0.38 0.37 0.28 0.59 0.9
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) -0.0707 x -0.5698 x -0.3566 x -0.3893 x -0.8835 x -2.022 x
Free Cash Flow 1 -0.28 -0.01 -0.9 -0.33 -0.31 -0.24
ROE (net income / shareholders' equity) 138% 63.7% 66.4% 58.8% 38.9% 22.5%
ROA (Net income/ Total Assets) -566% -355% -371% -429% -897% -387%
Assets 1 0.2732 0.255 0.2944 0.2124 0.0777 0.1279
Book Value Per Share 2 -0.0200 -0.0400 -0.0300 -0.0300 -0.0300 -0.0400
Cash Flow per Share 2 0 0 0 0 0 0
Capex - 0 0 0 - -
Capex / Sales - - 2.57% 23.28% - -
Announcement Date 9/13/18 9/6/19 9/15/20 8/30/21 4/7/23 9/1/23
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
CELL MEDX CORP. Stock Cell MedX Corp.
+36.36% 6.54M
MODERNA, INC. Stock Moderna, Inc.
+25.69% 48.09B
LONZA GROUP AG Stock Lonza Group AG
+46.90% 40.62B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.46% 40.43B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.36B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+9.17% 24.89B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.42% 19.01B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.07% 12.09B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.17% 11.88B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.24% 11.8B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. CMXC Stock
  4. Financials Cell MedX Corp.